STOCK TITAN

[SCHEDULE 13G/A] PolyPid Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.

The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.

Rosalind Advisors, persone correlate e un fondo dichiarano la titolarità beneficiaria collettiva di 5,762,349 azioni ordinarie di PolyPid Ltd., rappresentanti il 9.9% delle azioni in circolazione secondo la comunicazione dell'emittente che riporta 15,897,201 azioni in circolazione. La posizione riportata è composta da 975,462 azioni ordinarie e 4,786,887 azioni ottenibili mediante esercizio di warrant.

I depositi indicano la condivisione del potere di voto e di disposizione su 5,762,349 azioni e l'assenza di poteri di voto o di disposizione esclusivi. I warrant contengono una clausola di blocco che ne impedisce l'esercizio nella misura in cui aumenterebbe la partecipazione oltre il 9.99%, e il documento precisa che la proprietà effettiva, tenendo conto di tali blocchi, è inferiore agli importi segnalati.

Rosalind Advisors, personas relacionadas y un fondo informan una titularidad beneficiaria colectiva de 5,762,349 acciones ordinarias de PolyPid Ltd., que representan el 9.9% del capital en circulación según la divulgación del emisor, basada en 15,897,201 acciones en circulación. La posición informada consta de 975,462 acciones ordinarias y 4,786,887 acciones que pueden obtenerse mediante el ejercicio de warrants.

Las presentaciones muestran poderes compartidos de voto y disposición sobre 5,762,349 acciones y la ausencia de poder exclusivo de voto o disposición. Los warrants incluyen una cláusula de bloqueo que impide el ejercicio en la medida en que aumente la participación por encima del 9.99%, y la presentación indica que la propiedad real, tras tener en cuenta dichos bloqueos, es inferior a las cifras notificadas.

Rosalind Advisors와 관련자들 및 한 펀드는 PolyPid Ltd.의 보통주 5,762,349주에 대한 집단적 실질 소유권을 신고했으며, 이는 발행사가 공시한 15,897,201주를 기준으로 발행주식의 9.9%에 해당합니다. 보고된 포지션은 보통주 975,462주와 워런트 행사로 취득 가능한 4,786,887주로 구성됩니다.

서류에는 5,762,349주에 대해 투표권 및 처분권을 공동으로 보유하고 있으며 단독의 투표권 또는 처분권은 없다고 기재되어 있습니다. 워런트에는 보유비중이 9.99%를 초과하지 않도록 행사를 제한하는 차단 조항이 포함되어 있으며, 제출서류는 이러한 차단을 반영한 실제 소유량이 보고된 수치보다 적다고 명시하고 있습니다.

Rosalind Advisors, des personnes liées et un fonds déclarent une détention bénéficiaire collective de 5,762,349 actions ordinaires de PolyPid Ltd., représentant 9.9% du capital en circulation d'après la communication de l'émetteur indiquant 15,897,201 actions en circulation. La position déclarée se compose de 975,462 actions ordinaires et de 4,786,887 actions pouvant être obtenues par l'exercice de warrants.

Les dépôts indiquent qu'ils exercent des pouvoirs de vote et de disposition partagés sur 5,762,349 actions et qu'ils ne disposent d'aucun pouvoir exclusif de vote ou de disposition. Les warrants comprennent une clause de blocage empêchant l'exercice dans la mesure où il porterait la détention au-delà de 9.99%, et le dépôt précise que la détention effective, après prise en compte de ces blocages, est inférieure aux montants déclarés.

Rosalind Advisors, verwandte Personen und ein Fonds melden eine gemeinsame wirtschaftliche Beteiligung an 5,762,349 Stammaktien der PolyPid Ltd., was 9.9% des ausstehenden Stammkapitals entspricht, basierend auf 15,897,201 ausstehenden Aktien laut Offenlegung des Emittenten. Die gemeldete Position besteht aus 975,462 Stammaktien und 4,786,887 Aktien, die durch Ausübung von Warrants erworben werden können.

Die Unterlagen zeigen gemeinsame Stimm- und Verfügungsrechte über 5,762,349 Aktien und keine alleinigen Stimm- oder Verfügungsrechte. Die Warrants enthalten eine Sperrklausel, die die Ausübung in dem Umfang verhindert, dass die wirtschaftliche Beteiligung über 9.99% steigen würde, und die Einreichung stellt fest, dass das tatsächliche Eigentum unter Berücksichtigung dieser Sperren geringer ist als die gemeldeten Beträge.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A concentrated 9.9% position is disclosed, largely warrant-based, with blocker limits reducing immediate economic/control impact.

Rosalind Advisors, its named principals and Rosalind Master Fund L.P. report an aggregate 5,762,349-share position in PolyPid (PYPD). The position is materially composed of 4,786,887 warrant-linked shares, with only 975,462 shares as direct common stock. The presence of a blocker that prevents exercise above 9.99% is critical: it limits conversion risk and near-term dilution from warrant exercises. Shared voting/dispositive power indicates coordinated ownership among the reporting persons rather than independent, sole-control stakes.

TL;DR: Disclosure is comprehensive but the blocker and disclaimers reduce clarity on actual exercisable influence.

The Schedule 13G/A provides required transparency by quantifying both owned shares and warrant exposure. However, the filing also states the advisor and portfolio managers disclaim beneficial ownership of the shares held by the fund, and the blocker restricts warrant exercise above 9.99%. For governance analysis, the combination of shared powers, substantial warrant holdings and explicit disclaimers means stakeholder influence is limited and conditional, not an outright controlling position.

Rosalind Advisors, persone correlate e un fondo dichiarano la titolarità beneficiaria collettiva di 5,762,349 azioni ordinarie di PolyPid Ltd., rappresentanti il 9.9% delle azioni in circolazione secondo la comunicazione dell'emittente che riporta 15,897,201 azioni in circolazione. La posizione riportata è composta da 975,462 azioni ordinarie e 4,786,887 azioni ottenibili mediante esercizio di warrant.

I depositi indicano la condivisione del potere di voto e di disposizione su 5,762,349 azioni e l'assenza di poteri di voto o di disposizione esclusivi. I warrant contengono una clausola di blocco che ne impedisce l'esercizio nella misura in cui aumenterebbe la partecipazione oltre il 9.99%, e il documento precisa che la proprietà effettiva, tenendo conto di tali blocchi, è inferiore agli importi segnalati.

Rosalind Advisors, personas relacionadas y un fondo informan una titularidad beneficiaria colectiva de 5,762,349 acciones ordinarias de PolyPid Ltd., que representan el 9.9% del capital en circulación según la divulgación del emisor, basada en 15,897,201 acciones en circulación. La posición informada consta de 975,462 acciones ordinarias y 4,786,887 acciones que pueden obtenerse mediante el ejercicio de warrants.

Las presentaciones muestran poderes compartidos de voto y disposición sobre 5,762,349 acciones y la ausencia de poder exclusivo de voto o disposición. Los warrants incluyen una cláusula de bloqueo que impide el ejercicio en la medida en que aumente la participación por encima del 9.99%, y la presentación indica que la propiedad real, tras tener en cuenta dichos bloqueos, es inferior a las cifras notificadas.

Rosalind Advisors와 관련자들 및 한 펀드는 PolyPid Ltd.의 보통주 5,762,349주에 대한 집단적 실질 소유권을 신고했으며, 이는 발행사가 공시한 15,897,201주를 기준으로 발행주식의 9.9%에 해당합니다. 보고된 포지션은 보통주 975,462주와 워런트 행사로 취득 가능한 4,786,887주로 구성됩니다.

서류에는 5,762,349주에 대해 투표권 및 처분권을 공동으로 보유하고 있으며 단독의 투표권 또는 처분권은 없다고 기재되어 있습니다. 워런트에는 보유비중이 9.99%를 초과하지 않도록 행사를 제한하는 차단 조항이 포함되어 있으며, 제출서류는 이러한 차단을 반영한 실제 소유량이 보고된 수치보다 적다고 명시하고 있습니다.

Rosalind Advisors, des personnes liées et un fonds déclarent une détention bénéficiaire collective de 5,762,349 actions ordinaires de PolyPid Ltd., représentant 9.9% du capital en circulation d'après la communication de l'émetteur indiquant 15,897,201 actions en circulation. La position déclarée se compose de 975,462 actions ordinaires et de 4,786,887 actions pouvant être obtenues par l'exercice de warrants.

Les dépôts indiquent qu'ils exercent des pouvoirs de vote et de disposition partagés sur 5,762,349 actions et qu'ils ne disposent d'aucun pouvoir exclusif de vote ou de disposition. Les warrants comprennent une clause de blocage empêchant l'exercice dans la mesure où il porterait la détention au-delà de 9.99%, et le dépôt précise que la détention effective, après prise en compte de ces blocages, est inférieure aux montants déclarés.

Rosalind Advisors, verwandte Personen und ein Fonds melden eine gemeinsame wirtschaftliche Beteiligung an 5,762,349 Stammaktien der PolyPid Ltd., was 9.9% des ausstehenden Stammkapitals entspricht, basierend auf 15,897,201 ausstehenden Aktien laut Offenlegung des Emittenten. Die gemeldete Position besteht aus 975,462 Stammaktien und 4,786,887 Aktien, die durch Ausübung von Warrants erworben werden können.

Die Unterlagen zeigen gemeinsame Stimm- und Verfügungsrechte über 5,762,349 Aktien und keine alleinigen Stimm- oder Verfügungsrechte. Die Warrants enthalten eine Sperrklausel, die die Ausübung in dem Umfang verhindert, dass die wirtschaftliche Beteiligung über 9.99% steigen würde, und die Einreichung stellt fest, dass das tatsächliche Eigentum unter Berücksichtigung dieser Sperren geringer ist als die gemeldeten Beträge.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: This percentage is calculated based upon 15,897,201 Ordinary shares of the Issuers common stock outstanding as of July 27, 2025, based on the issuers F-3 Filing of July 29, 2025. However, as more fully described in Item 4, the securities reported in rows 6, 8 and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8 and 9. (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/13/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/13/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/13/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/13/2025
Polypid Ltd.

NASDAQ:PYPD

PYPD Rankings

PYPD Latest News

PYPD Latest SEC Filings

PYPD Stock Data

51.35M
7.11M
25.65%
49.04%
0.64%
Biotechnology
Healthcare
Link
Israel
Petah Tikva